Cited by

• Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements.

  Tavares V, Marques IS, Melo IG, Assis J, Pereira D, Medeiros R. Tavares V, et al. Int J Mol Sci. 2024 Feb 3;25(3):1845. doi: 10.3390/ijms25031845. Int J Mol Sci. 2024. PMID: 38339123 Free PMC article. Review.
• Hyperthermia Intensifies α-Mangostin and Synthetic Xanthones' Antimalignancy Properties.

  Rech J, Żelaszczyk D, Marona H, Gunia-Krzyżak A, Żmudzki P, Bednarek IA. Rech J, et al. Int J Mol Sci. 2024 Aug 15;25(16):8874. doi: 10.3390/ijms25168874. Int J Mol Sci. 2024. PMID: 39201559 Free PMC article.
• Hyperthermic Intraperitoneal Chemotherapy-Induced Molecular Changes in Humans Validate Preclinical Data in Ovarian Cancer.

  Dellinger TH, Han ES, Raoof M, Lee B, Wu X, Cho H, He TF, Lee P, Razavi M, Liang WS, Schmolze D, Priceman SJ, Lee S, Lin WC, Lin JF, Kebria M, Hakim A, Ruel N, Stewart DB, Wang EW, Paz BI, Wakabayashi MT, Cristea MC, Rodriguez-Rodriguez L. Dellinger TH, et al. JCO Precis Oncol. 2022 Mar;6:e2100239. doi: 10.1200/PO.21.00239. JCO Precis Oncol. 2022. PMID: 35357903 Free PMC article. Clinical Trial.
• Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.

  Gelissen JH, Adjei NN, McNamara B, Mutlu L, Harold JA, Clark M, Altwerger G, Dottino PR, Huang GS, Santin AD, Azodi M, Ratner E, Schwartz PE, Andikyan V. Gelissen JH, et al. Ann Surg Oncol. 2023 Sep;30(9):5597-5609. doi: 10.1245/s10434-023-13757-0. Epub 2023 Jun 26. Ann Surg Oncol. 2023. PMID: 37358686 Review.
• The emerging role of circular RNAs in cisplatin resistance in ovarian cancer: From molecular mechanism to future potential.

  Malek Mohammadi M, Rismanchi H, Esmailzadeh S, Farahani A, Hedayati N, Alimohammadi M, Mafi A, Farahani N, Hushmandi K. Malek Mohammadi M, et al. Noncoding RNA Res. 2024 May 20;9(4):1280-1291. doi: 10.1016/j.ncrna.2024.05.005. eCollection 2024 Dec. Noncoding RNA Res. 2024. PMID: 39040815 Free PMC article. Review.